Page 180 - Cellular Imaging in Regenerative Medicine, Cancer and Osteoarthritis

Chapter 8
20. Roose D, Leroux F, De Vocht N, Guglielmetti C, Pintelon I, Adriaensen D, et al. Multimodal imaging of micron-sized iron oxide particles following in vitro and in vivo uptake by stem cells: down to the nanometer scale. 2014;9(6):400-8.
21. Shapiro EM, Skrtic S, Koretsky AP. Sizing it up: Cellular MRI using micron-sized iron oxide particles. 2005;53(2):329-38.
22. Gilad AA, Winnard PT, Van Zijl PCM, Bulte JWM. Developing MR reporter genes: promises and pitfalls. 2007;20(3):275-90.
23. Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med. 2005;11(4):450-4.
24. Chapelin F, Capitini CM, Ahrens ET. Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. Journal for ImmunoTherapy of Cancer. 2018;6(1).
25. Srinivas M, Heerschap A, Ahrens ET, Figdor CG, Vries IJMD. 19F MRI for quantitative in vivo cell tracking. 2010;28(7):363-70.
26. Fox M, Gaudet J, Foster P. Fluorine-19 MRI Contrast Agents for Cell Tracking and Lung Imaging. 2016:53.
27. Ferrara K, Pollard R, Borden M. Ultrasound Microbubble Contrast Agents: Fundamentals and Application to Gene and Drug Delivery. Annual Review of Biomedical Engineering. 2007;9(1):415- 47.
28. Lentacker I, De Cock I, Deckers R, De Smedt SC, Moonen CTW. Understanding ultrasound induced sonoporation: Definitions and underlying mechanisms. Advanced Drug Delivery Reviews. 2014;72:49-64.
29. Kooiman K, Vos HJ, Versluis M, De Jong N. Acoustic behavior of microbubbles and implications for drug delivery. 2014;72:28-48.
30. Nowak-Sliwinska P, Segura T, Iruela-Arispe ML. The chicken chorioallantoic membrane model in biology, medicine and bioengineering. 2014;17(4):779-804.
31. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60(1):1-42.
32. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8(4):1139-1146.
33. Sancho V, Di Florio A, Moody TW, Jensen RT. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Current drug delivery. 2011;8(1):79-134.
34. Moreno P, Ramos-Álvarez I, Moody TW, Jensen RT. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. 2016;20(9):1055-73.
35. Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, et al. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. 2015.
36. Bakker I FA, Busstra MB et al PET imaging of prostate cancer using the GRPr-targeting ligand Sarabesin-3 prior to radical prostatectomy [abstract]. Eur J Nucl Med Mol Imaging. 2016;43:S1- S734.
37. Lymperis E M-NT, Kaloudi A et al. Transient in vivo NEP inhibition enhances the theranostic potential of the new GRPR antagonist [111In/177Lu]SB3 [abstract]. Eur J Nucl Med. 2014;41(s319).
38. Nock BA, Maina T, Krenning EP, De Jong M. “To Serve and Protect”: Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting. 2014;55(1):121-7.
39. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacological Reviews. 1993;45(1):87-146.
40. Kaloudi A, Nock BA, Lymperis E, Krenning EP, De Jong M, Maina T. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. 2016;31(1):20-8.
178